Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease
Cells · 09.08.2024 · 13 (16) · 1327
DOI: 10.3390/cells13161327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 09.08.2024. Verfasst von Monique de Fatima Mello Santana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-000, Brazil. Hauptthemen laut MEDLINE: Proteomics, Breast Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Fundaçao de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
The association between high-density lipoprotein (HDL) cholesterol and breast cancer (BC) remains controversial due to the high complexity of the HDL particle and its functionality. The HDL proteome was determined in newly diagnosed BC classified according to the molecular type [luminal A or B (LA or LB), HER2, and triple-negative (TN)] and clinical stage of the disease. Women (n = 141) aged between 18 and 80 years with BC, treatment-naïve, and healthy women [n = 103; control group (CT)], matched by age and body mass index, were included. Data-independent acquisition (DIA) proteomics was performed in isolated HDL (D = 1.063–1.21 g/mL).
Results
Paraoxonase1, carnosine dipeptidase1, immunoglobulin mMu heavy chain constant region (IGHM), apoA-4, and transthyretin were reduced, and serum amyloid A2 and tetranectin were higher in BC compared to CT. In TNBC, apoA-1, apoA-2, apoC-2, and apoC-4 were reduced compared to LA, LB, and HER2, and apoA-4 compared to LA and HER2. ComplementC3, lambda immunoglobulin2/3, serpin3, IGHM, complement9, alpha2 lysine rich-glycoprotein1, and complement4B were higher in TNBC in comparison to all other types; complement factor B and vitamin D-binding protein were in contrast to LA and HER2, and plasminogen compared to LA and LB. In grouped stages III + IV, tetranectin and alpha2-macroglobulin were reduced, and haptoglobin-related protein; lecithin cholesterol acyltransferase, serum amyloid A1, and IGHM were increased compared to stages I + II.
Conclusions
A differential proteomic profile of HDL in BC based on tumor molecular classification and the clinical stage of the disease may contribute to a better understanding of the association of HDL with BC pathophysiology, treatment, and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Lípides (LIM10), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-000, Brazil.
- Programa de Pós-Graduação em Medicina, Universidade Nove de Julho, Sao Paulo 01525-000, Brazil.
- Grupo de Saúde de Curitiba (GSAU-CT), CINDACTA II, Brazilian Air Force, Curitiba 82510-901, Brazil.
- Laboratório de Proteômica Aplicada à Processos Inflamatórios, Instituto de Química, Universidade de Sao Paulo, Sao Paulo 05508-900, Brazil.
- Unidade Básica de Saúde Dra. Ilza Weltman Hutzler, Sao Paulo 02472-180, Brazil.
- Laboratório de Carboidratos e Radioimunoensaio (LIM18), Hospital das Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-000, Brazil.
ORCID-Profile: Monique de Fatima Mello Santana, Maria Isabela Bloise Alves Caldas Sawada, Douglas Ricardo Souza Junior, Maria Lucia Côrrea-Giannella, Francisco Garcia Soriano, Luiz Henrique Gebrim, Graziella Eliza Ronsein, Marisa Passarelli
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fundaçao de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Santana, M. F. M., Sawada, M. I. B. A. C., Junior, D. R. S., Giacaglia, M. B., Reis, M., Xavier, J., Côrrea-Giannella, M. L., Soriano, F. G., Gebrim, L. H., Ronsein, G. E., & Passarelli, M. (2024). Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease. Cells, 13(16), 1327. https://doi.org/10.3390/cells13161327
Vancouver
Santana MFM, Sawada MIBAC, Junior DRS, Giacaglia MB, Reis M, Xavier J, et al. Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease. Cells. 2024;13(16):1327. doi:10.3390/cells13161327
BibTeX
@article{Santana2024,
author = {Santana, Monique de Fatima Mello and Sawada, Maria Isabela Bloise Alves Caldas and Junior, Douglas Ricardo Souza and Giacaglia, Marcia Benacchio and Reis, Mozania and Xavier, Jacira and Côrrea-Giannella, Maria Lucia and Soriano, Francisco Garcia and Gebrim, Luiz Henrique and Ronsein, Graziella Eliza and Passarelli, Marisa},
title = {Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease},
journal = {Cells},
year = {2024},
volume = {13},
number = {16},
pages = {1327},
doi = {10.3390/cells13161327}
}
EUVIMED